Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 18Other hematologic neoplasm 16Myeloid 14Genitourinary 6Gastrointestinal 5CNS 5Lymphoid 4Other solid neoplasm 2Gynecologic 2Tumor-Agnostic 1Sarcoma 1Other neoplasm 1Head & Neck 1Endocrine 1

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 2

Interventions

Cisplatin 145pembrolizumab 129Carboplatin 125Injections 108Pemetrexed 97Paclitaxel 97Gemcitabine 85Irinotecan 75Nivolumab 71Cyclophosphamide 71Docetaxel 68Bevacizumab 57Oxaliplatin 49Fluorouracil 48atezolizumab 46Capecitabine 46Etoposide 42Leucovorin 41tislelizumab 40toripalimab 36fludarabine 32Ipilimumab 30Drug Therapy 30Topotecan 29durvalumab 28Vincristine 27Early Intervention, Educational 27Radiotherapy 26Interviews as Topic 26Specimen Handling 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × peginterferon alfa-2b × Other solid neoplasm × Clear all
NCT00014261 2018-03-30

Temozolomide Plus PEG-Interferon Alfa-2B in Treating Patients With Advanced Solid Tumors

Dartmouth-Hitchcock Medical Center

Phase 1 Completed
Other solid neoplasm

Unspecified Adult Solid Tumor, Protocol Specific

NCT00701298 2014-02-24

Decitabine With or Without Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Solid Tumors

National Cancer Institute (NCI)

Phase 1 Terminated
30 enrolled
Other solid neoplasm

Unspecified Adult Solid Tumor, Protocol Specific

Data powered by HemOnc (CC BY 4.0) Colophon âš¡